STAT

LISTEN: Biotech’s six months of surprise, the shaky road ahead, and sell-side self-doubt

Why is everyone so down on biotech's household names? And if a stock gets downgraded in an analyst note, should anyone care? Find out on "The Readout LOUD."

Why is everyone so down on biotech’s household names? How do you become a day trader? And if a stock gets downgraded in

You're reading a preview, sign up to read more.

More from STAT

STAT3 min read
Opinion: CBO Estimate On Pelosi Drug Bill Misses Its Long-term Impact On Health
The CBO estimate on Speaker Nancy Pelosi's drug pricing bill misses its long-term impact on health.
STAT1 min read
Listen: Pharma’s Future In China, CRISPR Meets Netflix, & Where VC Dollars Come From
Should drug companies be free-speech advocates? Is your retirement dependent on CRISPR? And how useful is a glow-in-the-dark dog? All that and more on the new episode of "The Readout…
STAT4 min readSociety
An ‘Unprecedented’ Analysis Underlines Profound Failure To Study African Genomes
It has become the geneticist’s version of, “What, me not inclusive? But I have a black friend!” In the case of modern studies of DNA, researchers called to task for studying mainly European populations often defend themselves by pointing out that the